Laboratory management should be an integral part of training in pathology residency and fellowships. Herein, we have outlined some basic laboratory management topics a graduating cytopathology fellow should be familiar with. An overview of regulatory agencies that have oversight over laboratory testing, cytopathology laboratory accreditation, pre-analytic, analytic and post-analytic quality assurance, billing/coding, basic statistics, verification/validation of testing, physician credentialing, board certification/maintenance of certification, and malpractice in cytopathology are addressed. This review is by no means all inclusive, but rather a guide to the basic management related topics to be covered during cytopathology subspecialty training.
Introduction
Laboratory management should be an integral part of training in pathology residency and fellowships. Since 2014, the American Board of Pathology has participated in surveys of new in practice ( 10 years) pathologists that asked about how residency and fellowship training correlates with the needs in practice. The feedback has consistently shown that laboratory management, billing and coding, informatics, and molecular diagnostics are areas in which training was perceived to be less than needed, but important or very important areas for practice. Similar findings were published in 2007. 1 Herein, we have outlined some basic laboratory management topics with which a graduating cytopathology fellow should be familiar. An overview of regulatory agencies that have oversight over laboratory testing, cytopathology laboratory accreditation, preanalytic, analytic and post-analytic quality assurance, billing/ coding, basic statistics, verification/validation of testing, physician credentialing, board certification/maintenance of certification, and malpractice in cytopathology are addressed. This review is by no means all inclusive, but rather a guide to the basic management related topics to be covered during cytopathology subspecialty training.
Agencies involved in laboratory regulation
Health care is subject to extensive regulation at both the federal and the state level in order to ensure compliance and to provide safe health care to every individual who accesses the system. There are a number of historical examples in medicine in which lack of standards led to adverse outcomes. Specific to cytology is the exposé on "Pap mills" in the Wall Street Journal by investigative journalist Walt Bogdanich that played a major role in the implementation of the Clinical Laboratory Improvement Amendments of 1988. 2 Federal, state, and local regulatory agencies often establish rules and regulations for the health-care industry, and their oversight is mandatory. Some other agencies, such as those for accreditation, require voluntary participation but are important because they provide rankings or certification of quality and serve as additional oversight, ensuring that health-care organizations promote and provide quality care (Table 1) .
General aspects and basis of cytopathology laboratory accreditation
Fundamentally, accreditation is a way to ensure that clinical laboratories meet best practices for proficiency, quality, accuracy, and record keeping. To be accredited, a laboratory must set up and maintain mechanisms that are evaluated regularly by an outside entity. Accreditation signals to patients, doctors, and insurers that the laboratory is making every effort to provide them with high-quality, accurate results and that those results are reasonably translatable across accredited laboratories. 3 Laboratories in the United States that process clinical patient samples are regulated by the Centers for Medicare & Medicaid Services (CMS) ( Table 1) . CMS accredits nearly all clinical laboratories, usually through the proxies of deemed status inspectors provided by professional groups. For services to be covered by Medicare, there needs to be compliance with the Clinical Laboratory Improvement Amendments (CLIA) statute. CLIA was passed in 1967 but has undergone several amendments. CLIA'88 was the result of a two-part exposé in the Wall Street Journal in November 1987, with part 2 addressing less than optimal practices in cytology laboratories. 2 CLIA'88 specifically addressed cytopathology laboratory testing issues; cytology was classified as highcomplexity testing, and cytology-specific mandates were introduced ( Table 2 ). The final regulations were published in September 1992 and were implemented January 1, 1994. 5 Additional amendments followed in 1997 and 2012, but the cytology-specific initial mandates have not changed.
In addition to CMS, there are several other accreditation organizations for cytopathology laboratories, including the College of American Pathologists (CAP) 6 and the Joint Commission (TJC), 7 both of which are CMS-approved accreditation organizations (ie, provide "deemed" status), so laboratories accredited by these organizations are also CLIA-compliant. 8 More recently, the International Organization for Standardization has developed standards for quality management systems; however, it does not audit or certify laboratories and relies on third-party organizations to verify that the laboratory meets the relevant standards. 9 Accreditation organizations conduct onsite surveys of laboratories to ensure they meet the necessary requirements. Surveys must be conducted at least every 2 years to maintain CLIA compliance. Depending on individual state HIPAA An Act to amend the Internal Revenue Code of 1986 to improve portability and continuity of health insurance coverage in the group and individual markets, to combat waste, fraud, and abuse in health insurance and health care delivery, to promote the use of medical savings accounts, to improve access to long-term care services and coverage, to simplify the administration of health insurance, and for other purposes. Enacted in 1996 and consists of 5 titles. requirements, a separate inspection conducted by staff of the state department of health or similar agency may be required. The CAP Checklists provide detailed measures for laboratory quality management and quality control. 6 Cytopathology fellows should be familiar with the Cytopathology Checklist and the All Common Checklist and perform a mock laboratory inspection under the laboratory director's/ supervisor's oversight to become acquainted with the regulatory information required to manage a cytopathology laboratory. Table 2 outlines the cytology specific mandates under CLIA'88 that form the basis of the CAP Cytopathology Checklist. Specific laboratory pre-analytic, analytic, and post-analytic quality assurance measures in cytopathology laboratories
Specimen collection, receipt, and preparation
Fellows should be familiar with specifics of collection and transport of cytology specimens and have a good understanding of cytology preparatory techniques and know the basics of maintaining optimal technical quality in preparing and staining cytology specimens. All reagents are labeled for identity, titer, concentration, recommended storage, and expiration date. The stains and working solutions are dated when prepared and initialed by the person preparing the stain or solution; for commercial solutions the date they are received and opened is recorded. All stains and reagents are kept covered when not in use and stored at the proper temperature. Chemical safety, fire prevention, and biosafety hazard policies related to the laboratory specimen preparation should also be reviewed. Each specimen should be submitted with appropriate patient identification (a minimum of 2 unique identifiers), which should include the patient name, medical record number or date of birth, and, if applicable, the patient barcode for scanning the specimen into the laboratory information system.
Gynecologic cytology
Gynecologic specimens are processed separately from nongynecologic specimens. Currently, most gynecologic cytology specimens are submitted in liquid based media, either ThinPrepÔ or SurePathÔ, although conventional smears are acceptable for cervical cancer screening. For SurePath, cervical samples are collected using a broom-like device with a detachable head, which is placed in a vial with an ethanol-based preservative fluid and sent to the laboratory. The fluid and cells are then centrifuged to isolate the cells from the fluid; the cells are re-suspended in a sucrose density gradient, followed by slide transfer using gravity for adherence. For ThinPrepÔ, the cervical specimen is collected using a Cervix BrushÔ, and the brush is rinsed in a vial with a methanol-based preservative fluid by the caregiver. Cells are released by pushing the brush to the bottom and swirling the brush into the fluid. Subsequently, the brush is discarded. The specimen is sent to the laboratory, where the cells are then isolated from the fluid by vacuum filtration and are transferred to the slide using air pressure for adherence. 10 Issues related to lubricant and blood interference with adequacy of ThinPrep testing require quality-assurance measures with respect to educating providers and use of glacial acetic acid, respectively. Fellows should familiarize themselves with use of automation in cytology preparation and screening, including basic principles of the ThinPrepÔ imaging system/selection of 22 fields of view and the BD FocalPoint GSÔ imaging system that uses algorithms to determine potential. 11 The BD FocalPoint GS imaging system also offers location guided screening with 10 field of view capability. 12 Workload limits and workload calculations for cytotechnologists and primary screening pathologists, including the US Food and Drug Administration (FDA)eapproved workload calculation for semi-automated screening of gynecologic specimens and nongynecologic preparations, are required for compliance. 13 Human papillomavirus (HPV) testing may be performed in house in the molecular or cytopathology laboratory or sent to a referral laboratory. There are various types of highrisk HPV testing options, both DNA-and RNA-based. The relevance of testing only for high-risk viruses in cervical cancer prevention and the role of genotyping, especially HPV16/18, should be reviewed. 14, 15 Another area of importance in cervical cancer screening and management is integration of HPV testing and its results with cytology, as it relates to primary screening (HPV only and cotesting), triage, and follow up. [16] [17] [18] Cervical cancer screening is in flux in the United States; trainees and practioners need to keep themselves updated on new testing platforms and evolving screening and management guidelines.
Nongynecologic cytology
Conventional preparations such as smears, touch imprints/ crush preparations, and cytospins, as well as liquid-based methods are utilized for preparation of nongynecologic specimens, including fine-needle aspiration (FNA), body cavity fluid, cerebrospinal fluid, urine, bronchoalveolar lavage, bronchial brushing, and pancreaticobiliary brushing. Giemsa-based (Diff-QuikÔ), Papanicolaou, and hematoxylin and eosin staining protocols are used, with the former being utilized most commonly for rapid on site assessment. Although diagnostic criteria are similar, morphologic appearances vary in different preparations and stains. Fellows should familiarize themselves with the differences, advantages, and limitations of each. An excellent way to gain more experience with FNA cytology and core biopsy touch preparations is to use these techniques in the gross room, autopsy suite, and during intraoperative consultation, because this provides an additional real-time means of histologicecytologic correlation, especially for organ sites for which the program may have low volumes in the cytopathology laboratory. 18 Coverslipping methods and avoidance of artifacts such as "cornflaking" should be observed. There are a number of methods that can be used for preparation of cell blocks from nongynecologic and FNA specimens, including thromboplastin, Cellient, histogel, and collodion bag. 19 Pathologist-performed FNA, with or without ultrasound guidance, is part of fellowship training and requires supervision from the attending pathologist(s). A TJC mandated "time out" procedure for correct identification of the patient and biopsy site is required at the beginning of these procedures. When an FNA biopsy is performed, the first step is to verify the patient's identity using at least 2 identifiers, which can be the patient's name, birth date, or medical record number. Secondly, the procedure site must be properly marked to identify the area of the patient's body that is to be aspirated, and before the procedure starts, a third step or "time out" is initiated by the physician conducting the procedure to give all members of the clinical team an opportunity to perform a final verification of the correct patient, correct procedure, correct side, correct site, correct patient position, and availability of any special equipment that is needed for the procedure. The "time out" can be documented either as a note in the patient's medical record, or by incorporating it as part of the FNA report. 20 The fellow should learn to observe, practice, and document this "time out" process. In programs where pathologists do not perform FNA, training with a radiologist can be offered; certification and/or continuing education courses conducted by professional organizations such as the CAP and American Society of Cytopathology are also available.
Fellows should be familiar with the requirements for sample adequacy techniques for preparation of good FNA smears, collection methods/preservation of cytologic specimens for molecular testing, and other relevant ancillary testing such as thyroglobulin, parathyroid hormone, flow cytometry, and cytogenetics.
Diagnostic interpretation
Cytopathology specimens typically undergo screening by cytotechnologists before final sign-out by a pathologist. The screening process involves locating and marking cells of diagnostic interest. Gynecologic cytology slides that are identified as negative for intraepithelial lesion or malignancy (NILM) can be signed out by a cytotechnologist. Any case with reactive/reparative changes or epithelial cell abnormality requires triage to a pathologist for final interpretation. Nongynecologic, anal cytology, and FNA cases can also be screened by the cytotechnologist, but must be signed out by a pathologist.
Criteria for diagnostic interpretation of gynecologic, nongynecologic, and FNA are an essential part of the core fellowship curriculum. There are a number of wellestablished standardized cytology reporting systems used in clinical practice. Examples include the Bethesda systems for cervical cytology and thyroid cytology, and more recent ones such as the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology, the Paris system for urinary cytology, the Milan system for salivary gland cytology, and the Lower Anogenital Tract Standardized Terminology for reporting HPV-associated squamous lesions of the lower anogenital tract. Trainees should be familiar with these reporting systems and their implications for patient management. [21] [22] [23] [24] [25] [26] Results of ancillary studies such as immunohistochemistry, flow cytometry, and molecular testing, when available, should be reviewed and correlated with morphology for final interpretation of cases, and such results should be clearly documented in the report. Knowledge of molecular changes, indications for using these tests, and testing methodologies used in various tumors originating from the lung, thyroid, colon, gastroesophageal junction, skin (melanoma), and so on, should be part of the cytopathology training curriculum.
Cytology histology correlation
The cytopathology laboratory should have a program for correlating histologic cases that are associated with cytologic specimens. There is no standard method for this quality assurance activity, although ideally all cytology reports with corresponding surgical pathology follow-up should be reviewed and discordant cases undergo review of the cytology and histology slides. 27 In some laboratories, the term "error" is avoided because of negative connotations; alternative terms, such as discrepancy or variance, can be used. It is well established that colposcopy and biopsy are not gold standards, and follow-up is warranted if biopsy following a high grade/malignant cytology is negative. Findings from the cytologicehistologic review should be documented and classified as sampling or interpretation variances. The majority of cytologicehistologic variances are due to sampling, either on cytology or on histology. Interpretation variances can further be subclassified as minor and major, and at least major variances should be shared with the involved cytotechnologist and/or pathologist. Discrepancies may also be due to locator problems, where a lesion may not have been identified due to the observer not visualizing the area of interest. The course of action will vary based on the nature/timing of detection of the variance. Amended reports are only warranted if current patient care is impacted. 28 Follow-up letters may be issued to clinicians, especially in major cervical cytologyehistology sampling variances. This is an excellent educational opportunity, and cytopathology fellows should be involved in reviewing these cases to appreciate its significance for laboratory quality assurance and patient management.
Management implications of cytopathology results
Fellows should understand the clinical implications of cytopathology interpretations for screening and diagnostic tests. Several professional organizations have screening and/or management guidelines tailored to specific cytopathology/surgical pathology testing methods and/or interpretations. Examples include screening and management guidelines for cervical cancer from the American Society for Colposcopy and Cervical Pathology and for thyroid FNA from the American Thyroid Association. 16, 29 Knowledge of recent, relevant developments in companion diagnostics for targeted therapies and prognostic and therapeutic ancillary studies is an important part and parcel of clinical practice. Familiarity with preventive measures such as HPV vaccinesdtheir composition, delivery indications, role in prevention of cervical cancer, and impact on the sensitivity of cervical cytology and high risk HPV testing in screeningdis warranted. 30 
Federally mandated gynecologic cytology proficiency testing
Under CLIA'88 guidelines, each laboratory involved in gynecologic cytology must enroll in an approved proficiency testing program, and individual cytotechnologists and pathologists involved in screening and/or evaluating gynecologic cytology are required to pass a CMS-approved gynecologic proficiency test annually. 31 The test set must contain at least 1 slide from each of the following 4 Bethesda interpretation categories: unsatisfactory, NILM, low-grade squamous intraepithelial lesion (LSIL), and highgrade squamous intraepithelial lesion (HSIL)/cancer. Each cytotechnologist receives a 10-slide test to screen in the same manner as they do patient specimens, and write their interpretation on their score sheet. Physicians who perform any primary screening (screen slides that have not been prescreened by a cytotechnologist) must be tested in the same manner as a cytotechnologist. Physicians who examine slides after they are pre-screened by a cytotechnologist may choose a set of test slides that have been previously screened and dotted by cytotechnologists or they may examine a set of slides that have not been previously screened and dotted. If the physician chooses to examine a pre-screened set, the cytotechnologist's diagnosis will accompany the test set. A passing score for all test takers is 90%, although the scoring grid differs for cytotechnologists and pathologists. Primary screening pathologists are graded using a pathologists' grid. 31 Initially, individuals are required to take a 10-slide test; and if they pass they do not need to be tested again until the following year. If the individual fails the first 10slide test, they must take a 10-slide retest within 45 days after notification of test failure. If the individual fails the second 10-slide retest, they must obtain documented, remedial training in the area of test failure, which will be noted on the test results letter. All Papanicolaou tests screened by the individual subsequent to the notification of second failure must be re-examined, and the individual must successfully pass a 20-slide test. If the individual fails the third, 20-slide, test, they must cease examining gynecologic cytology immediately upon notification of failure, and obtain at least 35 hours of documented, formally structured, continuing education in gynecologic cytology, and successfully participate in another 20-slide proficiency test. This final cycle can continue until the individual successfully participates in another 20-slide test. This measure was finally implemented nationwide in 2005. Since 2008, the failure rate has been at 2% to 3% for cytotechnologists and pathologists who are secondary screeners and 8% to 12% for primary screening pathologists. 32 Cytopathology fellows and residents are exempt from proficiency testing during training and in the year in which they receive board certification but are required to enroll after this period if they will be involved in interpretation of gynecologic cytology in their clinical practice. 33 Additional laboratory management essentials for cytopathology fellows Test 
validation and verification
Clinical laboratory tests are classified into waived and nonwaived tests by CLIA'88. Before any non-waived test is implemented for clinical use, vigorous validation or verification is required. The process of validation/verification requires the clinical laboratories to conduct and carefully document designed experiments/studies to evaluate the new assay and its performance characteristics to ensure reliable, reproducible, and accurate results for the intended application.
For tests approved by the FDA, CLIA requires verificationda laboratory must demonstrate its ability to obtain performance specifications, including accuracy, precision, reference range, and reportable range (Table 3) , established by the manufacturer during the FDA trial. For tests that have not been cleared or approved by the FDA, or those tests developed in-house (laboratory-developed test [LDT]) and FDA-cleared/approved tests modified by the laboratory, CLIA requires validationda laboratory must provide objective evidence through a defined process that a test performs as intended. 34, 35 In addition to the 4 performance specifications that are required for FDA cleared/ approved tests, the laboratory is expected to determine analytic sensitivity, analytic specificity including interference, and any additional relevant performance characteristics (specimen stability, linearity, etc) ( Table 3) .
For laboratory tests in which the outcome variable is binary (eg, high-risk HPV status), the most commonly used measures of performance include sensitivity, specificity, positive (PPV) and negative predictive values (NPV); all of which can be estimated by constructing a 2 Â 2 contingency table and determining the number of true positive (TP), true negative (TN), false positive (FP), and false negative (FN) from the validation data set. It is important to recognize that PPV and NPV vary depending on the prevalence of the disease being tested, whereas, sensitivity and specificity do not. By plotting the TP rate (the sensitivity) against the FP rate (equivalent to 1 e [specificity]), one can obtain the receiver operator characteristic (ROC) curve. Each point on the ROC curve represents a sensitivity/specificity pair that corresponds to a particular cutoff point for a particular assay. By calculating the area under each ROC curve (AUC), one can compare the ability of two or more tests to discriminate between the two outcomes; the larger the area under the curve, the better the discriminatory ability of the test. Cohen's kappa statistic can be used to determine the degree of agreement between two tests that yield categorical or ordinal data that can be compiled in N Â N tables. Kappa scores range from 1 to 0, with 1 indicating perfect agreement and 0 indicating no agreement. For tests that yield continuous data, paired t test and linear regression are often used for comparing the levels of performance between two assays.
Neither CLIA nor CAP specify requirements for validation or verification with regard to number of samples, criteria of acceptability, statistical analysis, and so forth. Therefore, laboratory directors are responsible for determining these specifics. In general, validation for a LDT or modified FDA cleared/approved test generally entails larger studies with more samples than are required to verify a FDA cleared/approved test. 35 There are a few exceptions; for example, CAP specifies the minimum number of samples required for the validation of HER2, ER, and PR tests as well as the minimum concordance acceptability threshold for ER/PR in breast carcinoma tissue.
Informatics and telemedicine
The laboratory information system (LIS) is a critical tool in workflow management, specimen tracking, patient information archiving, accurate and timely delivery of cytology reports to providers, as well as facilitation of quality management and regulatory compliance for clinical practice. The LIS consists of both hardware and software components. LIS software comprises a database management system that manages a central, relational database and LIS hardware includes computers such as servers and workstations as well as peripheral devices such as printers, barcode readers, and so on. An interface connects the LIS with instruments, such as imaging systems or HPV testing instruments, and other information systems such as the electronic medical record system. 36 Increasingly, digital imaging, including the use of static images, real-time video streaming, and whole slide imaging (WSI), is incorporated into clinical cytopathology practice, allowing cytologists to remotely evaluate cytologic preparations without being locally tethered to a conventional light microscope. One challenge of WSI unique to cytology is the difficulty in focusing on cytology material as a result of obscuring material or presence of 3dimensional cell groups; one solution is to perform zstacking of multiple images in different vertical (focal) planes. Telecytology has been increasingly utilized for rapid onsite evaluation at remote locations and can be performed using static images, real-time video streaming with or without the use of robotic microscopy, or WSI. If a laboratory is involved in adequacy assessment of FNAs at an offsite location, then telecytology may be utilized by the pathologists for assessing adequacy of the specimen. The laboratory must perform a validation study for the telecytology system utilized and train each cytotechnologist and pathologist who participates in this process. 37, 38 A billing process with adequate documentation should also be established. Fellows should also familiarize themselves with principles of microscopy, including Köhler illumination, photomicroscopy, and scanning of slides. The latter are increasingly used for archiving and documenting information about cases.
Statistics
Practicing pathologists routinely use statistics when signing out cases, interpreting ancillary test results, reviewing the literature, and conducting research. For example, when signing out a case, a differential diagnosis is considered, after taking into consideration the clinical history, morphology, and results of applicable ancillary studies. Statistics underline the composition and ranking of such a list. Statistics are also frequently utilized in research to design a study, analyze results, and evaluate validity of the study. The following is not intended to be an extensive review of statistics but to Table 3 Definition of performance specifications as related to validation and verification.
Performance specifications Definitions
Accuracy The closeness to the "true" value the new method can achieve by comparing the results of the new method with known values from the reference sources, another certified laboratory's results, or with results from the current method.
Precision (reproducibility)
The ability of the new method to duplicate the same results "between runs" (ie, will the test have the same result for the sample on different runs on different days?) and also "within run".
Reportable range
The highest and lowest test values that can be analyzed while maintaining accuracy. For tests depending on a cutoff value to determine positive results, testing positive specimens near the cutoff can serve as the cutoff validation.
Reference range
Normal values provided by the manufacturer or published from textbooks or scientific articles and can be verified by running known normal patient samples provided that the laboratory has a similar patient population.
Analytic sensitivity
The lowest concentration of the analyte that the test can reliably detect as positive in the given matrix.
Analytic specificity
The ability to detect only the analyte that it is designed to identify or quantify in the presence of interfering or cross-reactive substances.
provide a study framework for achieving a working understanding of statistics applicable to cytopathology (Table 4 ).
In the process of designing the study, one would generate a question or a hypothesis, which is followed by devising a method for testing the hypothesis as well as estimating the minimal sample size (ie, statistical power analysis) that will have the power, usually 80%, to reject the null hypothesis. Hypothesis testing starts with proposing a null hypothesis (there is no difference, there are no effects, etc.). The P value, or level of significance, is the probability of falsely rejecting that null hypothesis or the type I error rate (a). P values should almost always be 2-sided. In contrast, type II error rate (b) is the probability of falsely accepting the null hypothesis; the power to reject the null hypothesis is defined as 1 minus b.
It is important to be familiar with variables (ie, things that can be measured, manipulated, and analyzed) when conducting research. Variables can be classified as nominal, ordinal, interval, and ratio according to the type of measurement scale. Descriptive statistics are used to quantitatively describe or summarize variables and include mean, median, range, standard deviation, confidence interval, and shape of the distribution. Typically, one would be interested to know how well the distribution of a variable can be approximated by the normal distribution (ie, symmetrical distribution). The confidence interval is a type of interval estimate of a variable or parameter, whereas the confidence level refers to the frequency/probability that the observed interval contains the true variable if the experiment is repeated. The confidence level is the complement of the level of significancedfor example, a 95% confidence interval equates a significance level of 0.05.
When analyzing continuous (interval or ratio) data, the most frequently used statistical tests are Student t test, 44 which is used to determine whether two sets of data are significantly different from each other; ANOVA, or analysis of variance, 45 which is used for comparing 3 or more sets of data for statistical significance; and linear regression, 46 which is used for modeling the relationship between a dependent variable and one or more independent variables and is represented by Pearson correlation coefficient. 39 These parametric statistical procedures rely on the assumption that the underlying populations from which the samples derived are normally, or at least symmetrically, distributed. On the contrary, nonparametric statistical procedures do not rely on the assumptions about the shape of distribution of the underlying population and are widely used for studies with nominal and/or ordinal variables, such as comparing the nuclear grades of ER-positive and ERnegative breast carcinomas.
A contingency table or cross tabulation 47 shows the observed frequencies of data elements classified according to two variables with rows representing one variable and the columns indicating the other variable; it is used for examining relationships between categorical (nominal or ordinal) variables. The c 2 test 48 is the most common test for evaluating the null hypothesis that 2 categorical variables are independent by determining whether there is any significant difference between the expected and observed frequencies in one or more categories. Fisher's exact test 49 should be used instead of the c 2 test when the expected numbers are small; the usual rule of thumb for deciding whether the former is more suitable is when the expected values in any of the cells of a contingency table are less than five.
Concordances and reproducibility analyses are commonly used in pathology studies and include several methods such as percent agreement, intraclass correlation coefficient, and kappa statistics. Intraclass correlation coefficient 50 deals with continuous variables and is suitable for comparing two methodologies of instruments for measuring quantitative data in question and when the question of how closely these methods or instruments agree arises, whereas the kappa statistic 51 is suitable for assessing the degree of agreement between two raters for categorical (nominal) ratings. When comparing ordinal ratings, one may wish to use weighted kappa, namely, assigning less weight to agreement as categories are further apart (eg, when evaluating cervical Papanicolaou tests, a disagreement of NILM versus ASC-US could still be considered as partial agreement, but a disagreement of NILM versus HSIL would be counted as no agreement).
Regression analysis 52 is used to determine which independent variables are related to the dependent variable and to explore the forms of these relationships. It is often used for predicting and forecasting the outcome of a categorical variable of interest. The simplest form is simple linear regression, 53 which involves one independent variable (x) and a linear relationship between x and the dependent variable (y); the null hypothesis is that no linear relationship exists between x and y. Multiple linear regression involves multiple independent variables (x 1 , x 2 , ., x p ). Logistics regression 54 relates a binary outcome to one or more independent variables or predictors. Survival analysis 55 refers to statistical methods for analyzing longitudinal data on the occurrence of dichotomous events (yes/no) such as death, development of tumor recurrence, and so forth. It can be used for randomized clinical trial or cohort study design, both prospective and retrospective. Some of the tools include Kaplan-Meier curves 56 for describing the survival times of members of a group, log-rank test 57 for comparing the survival times of two or more groups, and Cox proportional hazards regression for describing the effect of categorical or quantitative variables on survival. The reader is referred to additional resources. [58] [59] [60] [61] Physician/professional regulation In order to practice pathology, having successfully finished medical school and postgraduate training in pathology is the basic requirement. If practicing in the United States, a physician must also have a valid medical license in the state of the practice (or any state if practicing for the federal government), have the required credentials for the privileges they will need for credentialing by the hospital medical staff office, and ideally be board-certified by the American Board of Pathology. Table 5 defines and explains these steps.
Professional practice evaluation (PPE)
Throughout the education and certification process, a physician's skills and knowledge are assessed. For decades, physician evaluation by hospital medical staff offices occurred every 2 years with a subjective and often minimalistic approach to renewal of privileging and credentialing. In 2007, TJC announced a new requirement for hospitals to evaluate their providers objectively and regularly. 62 This TJC mandate included two forms of evaluation: Ongoing Professional Practice Evaluation (OPPE) and Focused Professional Practice Evaluation (FPPE). OPPE was intended to be a means of performance evaluation conducted on an ongoing basis, and must occur more frequently than every 12 months. The aim was to monitor competency, identify areas for improvement, and use objective data in decisions for continuation of privileges. OPPE information is factored into the decision to maintain, revise, or revoke existing privileges at the time of renewal. FPPE involves more specific and time-limited monitoring of performance and is used specifically in the following situations: (1) when a provider is granted privileges for the first time, (2) when additional/new privileges are requested for an already privileged provider, and (3) when performance problems involving a privileged provider are identified (either through the OPPE process or by any other means, such as complaints or significant alteration from accepted practice). The FPPE process should be clearly defined and documented with evaluation criteria and a monitoring plan. The process should be performed in predetermined durations and have measures for acceptable performance.
The PPE is based on evaluation of the 6 competenciesdpatient care, medical knowledge, practicebased learning and improvement, interpersonal and communication skills, professionalism, and systems-based practicedthat were originally defined in 1999 by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties (ABMS) for outcome-based evaluation of residency training programs. The methodology and the timing of the evaluation are mostly left up to the individual organizations, although many perform OPPE every 6 months. It is the organized medical staff of the health care organization that ultimately must approve the number and type of metrics monitored for any individual practitioner or group of similar practitioners. In addition, although TJC recommends that an OPPE/FPPE program be organized into these 6 competencies, it is not required that all 6 areas be monitored for a given practitioner. 63, 64 Certification by the American Board of Pathology (ABP)
In June 1935, the American Medical Association (AMA) Section on Pathology and Physiology and the American Society for Clinical Pathology (ASCP) appointed committees that together considered the feasibility and desirability of establishing a national certifying board. In May 1936, the ASCP and the AMA Section on Pathology and Physiology accepted the proposed bylaws, authorized the nomination of 4 members each to the ABP, which was incorporated in Michigan. Approval of the ABP was granted by the Advisory Board for Medical Specialties (ABMS) and the AMA Council on Medical Education and Hospitals. On July 19, 1936, the ABP met for the first time in Chicago. The mission of the ABP, as a member of the ABMS, is to promote the field of pathology and the continuing competency of practicing pathologists. The ABP does not confer a legal qualification or license to practice pathology, does not delineate who may or may not engage in the practice of pathology or obtain hospital privileges, nor does it define the scope of specialty practice. After successful completion of ACGME or RCPSCaccredited training, obtaining a full and unrestricted medical license, and passing a rigorous examination, a pathologist can become a diplomate of the ABP. The ABP nominates pathologists to serve in 4 positions on the ACGME Residency Review Committee, and thus participates in the review of pathology training programs and assists in setting training program requirements. 65 
Maintenance of certification for pathologists
Maintenance of certification (MOC), or continuing certification, assists physicians in maintaining standards necessary for them to provide quality care throughout their careers. In addition, it assures the public that the physician is committed to lifelong learning and competency in pathology. The program requires ongoing assessment of the 6 competencies adopted by the ACGME and the ABMS to ensure that all aspects of practice are evaluated and outcomes are measured. As of January 1, 2006, all primary and subspecialty certificates issued by the ABP are timelimited, and diplomates are required to participate in the MOC program to maintain their certification. Continuing certification status is contingent upon meeting all requirements and deadlines of the program during each 2-year MOC cycle. 66, 67 A physician with residency training in Anatomic and Clinical Pathology has acquired the credentials to perform the duties of a pathologist practicing in either Anatomic or Clinical Pathology. Of note, a physician does not need to be board certified to practice, but he/she does need to be licensed in the state they practice. Credentialing
The process used to evaluate and verify a physician's qualifications and competence to practice medicine at a specific institution or hospital.
Credentialing is performed by the medical staff office of the specific institution at which the physician will be practicing. It usually requires a multitude of forms to be filled out by the physician to include demographic information, training, previous work, licensure information, continued medical education to upkeep the licensure, and legal issues regarding licensing, physician's practice, etc.
Privileges
The services and procedures that are within the physician's scope of practice.
Privileges can be highly specific (e.g., ultrasoundguided fine-needle aspiration) or can be more general (e.g., performing fine-needle aspiration). If they are highly specific, they can be grouped by common or like procedures into "privilege bundles". Privileging
The process in which a hospital determines the services and procedures that a physician is allowed to perform in the hospital. This usually occurs after the hospital has verified the physician's credentials.
Usually for privileging, the referees determined by the physician are queried for the competency of the physician for the required privileges. In addition, verification of training is completed from information provided by the postgraduate program from which the physician graduated. Licensing
Medical licensing is the procedure that the state medical boards in the U.S. uses to license and discipline allopathic and osteopathic physicians. In some jurisdictions, other health care professionals, other than physicians (e.g., physician's assistants) can also be licensed by the state medical board.
In the United States, in order to practice medicine a physician must have a valid license in the state they are practicing. The federal government does not grant licenses. This usually requires verification of graduation from medical school and postgraduate training among others. Individual states may have different regulations to confer a medical license.
Board Certification
The American Board of Pathology (ABP) certifies physicians who have successfully completed ACGME or Royal College of Physicians and Surgeons of Canada (RCPSC) accredited postgraduate training in pathology and have successfully passed the examination administered by the American Board of Pathology.
The ABP certifies physicians in Anatomic and Clinical Pathology, Anatomic Pathology, Clinical Pathology, and 11 subspecialties. Certification requirements can be found in the ABP Booklet of Information at www.abpath.org.
As of 2017, the ABP's MOC program consists of 4 parts:
Part I e Professionalism and Professional Standing: The diplomates must hold a valid, unrestricted medical license, meet the ABP's professionalism expectations, and abide by the AMA's or the American Osteopathic Association's Code of Ethics.
Part II e Lifelong Learning and Self-Assessment: The diplomates must meet the ABP's learning and selfassessment requirements.
Part III e Assessment of Knowledge, Judgment, and Skills: The diplomates must assess their pathology specific knowledge, judgment, and skills by passing a secure examination once every 10 years.
Part IV e Improvement in Medical Practice: The diplomates must engage in specialty relevant performancein-practice assessment and improvement activities.
Billing and coding with applicable health care laws
In order for laboratories to receive payment from CMS and TriCare, they must maintain a CLIA certificate, adhere to CLIA'88 regulations, and be reaccredited by the CAP or the TJC every 2 years. When a laboratory submits a claim to bill for a laboratory test, the claim must include the date and location of the service, a procedure code, and an International Classification of Diseases, 10th revision, Clinical Modification (ICD10-CM) code, which is used for medical necessity justification. There are two types of procedure codes for the service(s) being billed. One common terminology used in the United States is the current procedural terminology (CPT), which is owned and maintained by the AMA. Each laboratory ("technical") and physician ("professional") service provided by the cytopathology laboratory has an associated 5-digit CPT code, and these codes are published annually by the AMA, with new codes added and old codes deleted. Occasionally, guidance or clarification is provided on certain codes during the year, in between annual updates. For the most current code listing, please see the most recent edition of the AMA CPT Professional code book. Table 6 lists representative relevant CPT codes in cytopathology.
Another coding system that is maintained by CMS are the Healthcare Common Procedure Coding System (HCPCS) codes, which are used to describe supplies, drugs, and other services that are not included in CPT codes. The only HCPCS codes that are applicable to cytology are those for routine and high-risk screening Papanicolaou tests, which are summarized in Table 7 . A Papanicolaou test is classified as either screening (routine), screening (highrisk), or diagnostic for CMS purposes. When a woman has no current abnormal signs or symptoms within the female reproductive system, no prior abnormal Papanicolaou tests, and no high-risk factors for cervical or vaginal cancer, the Papanicolaou test is defined as a screening (routine) test. A Papanicolaou test is considered a screening (high-risk) test when the patient has a history of early onset of sexual activity (<16 years old), a history of 5 or more sexual partners, a history of HIV infection, or is the daughter of a woman who used diethylstilbestrol during pregnancy. Conditions that define a diagnostic Papanicolaou test include significant complaints, signs or symptoms in the female reproductive system, prior history of vaginal, cervical, or uterine cancer, or current abnormal findings of the vagina, cervix, uterus, or ovaries. Of note, only the referring physician can classify a Papanicolaou test as either screening (routine), screening (high-risk) or diagnostic. When the cytology laboratory realizes that the referring physician may have ordered the Papanicolaou test incorrectly, the lab should contact the referring physician and amend the order only after obtaining authorization to do so. The reasons that these definitions are important is that billing for the test depends upon its classification. Only diagnostic Papanicolaou tests are given a CPT code, whereas routine and high-risk screening Pap tests are given HCPCS codes for billing purposes.
With regard to FNAs performed by a clinician in which the pathologist performs a rapid on-site evaluation, each decision that a pathologist makes that results either in the continuation or conclusion of the procedures is termed an "evaluation episode". Each evaluation episode must be carefully documented during the FNA procedure, as one or more needle passes may be part of a single evaluation episode. The first evaluation episode of an FNA performed by a clinician with slides reviewed by a pathologist is coded as 88172, and each additional evaluation episode is coded as 88177. Of note, these codes are only used when the clinician is performing the FNA. Pathologist-performed FNAs without image guidance are coded as 10021 and those performed with image guidance are coded as 10022. For pathologistperformed FNAs, only a single 88172 should be billed, regardless of how many passes or evaluation episodes are performed. The initial evaluation episode for touch preparation rapid on-site evaluations of core-needle biopsies performed by a clinician is coded as 88333, with each additional evaluation episode being coded as 88334. The code for FNA interpretation and report is 88173, and this should not be billed if the specimen received is completely acellular.
Additional rules relevant to billing in cytology are the fact that codes 88108 (concentration technique) and 88112 (selective cell enhancement) cannot be billed together on the same part. In addition, 88112 (selective cell enhancement) and 88173 (FNA interpretation and report) cannot be billed together. Additional information on billing and coding practices in cytopathology can be found in relevant textbooks.
Stark Law
The Stark Law 68 addresses physician self-referral for CMS patients. From section 1877 of the Social Security Act, it is named after Congressman Pete Stark who sponsored the first version of the bill. The law states that a physician may not refer patients to an entity for a designated health service (DHS) if the physician or his or her immediate family member has a financial relationship with the DHS, unless an exception applies. The goal of the law is to prevent physician self-referrals and limit overutilization of services that drives up health-care costs. Stark I, effective January 1, 1992, prohibits physician self-referral for clinical laboratory services for Medicare patients. Stark II expanded the regulations under Stark I to include both Medicare and Medicaid patients and introduced further restrictions regarding self-referral for additional DHS beyond clinical laboratory services. The law specifically states that if an entity provides a DHS by an inhibited referral, the entity may not submit a claim to Medicare for that service. Likewise, no Medicare payments will be made for DHS claims under a prohibited physician referral. When Stark II passed, concerns were raised with regard to the intrusion of this legislation into the practice of medicine, particularly in relation to physician participation in managed care networks and the accompanying complexity of payment arrangements. Phase III of the Stark law, which excludes some of the banned DHS and repeals the prohibitions based on compensation arrangements in Stark II, was published on March 26, 2008.
The Sunshine Act
The Physician Payments Sunshine Act 69 is a health care reform law that was a component of the Affordable Care Act signed into law in 2010. As a part of this Act, medical product manufacturers and global purchasing organizations (GPOs) are required to report any payments or other transfers of value given to physicians (doctors of medicine, osteopathy, dentistry, optometry, podiatry, and chiropractic medicine) or teaching hospitals to the CMS. The medical product manufacturers include companies that manufacture pharmaceuticals, medical devices, and biologics. The Level IV e Surgical pathology gross and microscopic examination (cell block and some core biopsies); certain core biopsies may be coded as 88307 (Level V) 88312
Special stains for microorganisms 88313
Other histochemical stains (ie, mucin) 88342
Immunohistochemical stains first stain (qualitative) 88341
Immunohistochemical stains each additional stain (qualitative) 88360
Immunohistochemical stains (quantitative) 88321
Review of outside slides Abbreviations: FISH, fluorescence in situ hybridization; FNA, fine-needle aspiration. 
Malpractice in cytopathology
The Doctors Company, a physician-owned professional liability insurance company in Napa, California, is one of the nation's largest insurers of physician and surgeon liability. Their records showed that pathology is a low-claim frequency specialty, and the "average" pathologist had a claim every 12 years. Types of pathology claims include false-negative diagnosis of cancer, false-positive diagnosis of cancer, and systems error. Many are frivolous and companion claims that do not pay indemnity, and the pathologist is not the focus. 70 Although not all medical errors result in litigation, a survey of legal claims is one method of identifying errors that generate adverse outcomes. Kornstein, in a review on medicolegal aspects of pathology, identified records of 171 pathology legal cases from 1988 through 2005. Nearly half involved surgical pathology; among the remainder, cytology cases slightly outnumbered those pertaining to clinical pathology. 71 Among the 48 cases related to cytology, 37 involved falsenegative cervical cytology; less common were cases related to FNA of the breast, FNA of the thyroid, and FNA/exfoliative lung cytology. Gynecologic cytology has ranked among the top three causes of pathology litigation, although it has decreased in frequency in the past several years, likely due to utilization of liquid based preparations, HPV testing, automation, use of standardized Bethesda reporting terminology, and management guidelines that are synchronized with reporting terminology. Additionally, practices now have more subspecialty-boarded pathologists, and there are newer, more stringent requirements for continuing medical education and maintenance of certification. In FNA cytology, use of techniques such as EBUS and EUS pose new challenges and pitfalls, and these, as well as interpretation of stains and molecular tests that are now linked to specific therapies, are likely to become relatively more frequent in litigation related to cytopathology.
In addition to being sued for alleged misdiagnosis, cytopathologists may be named in lawsuits not because the cytology report is the immediate issue, but because all potentially liable parties must be named before the statute of limitations (the time period in which a lawsuit must be filed) runs out. Negligence is the predominant theory of liability underlining medicolegal issues, making this type of litigation part of tort law. A person who alleges a pathologist showed negligent medical malpractice must prove four elements: (1) a duty of care was owed by the pathologist; (2) there is a breach of the applicable standard of care; (3) the person suffered a compensable injury; and (4) the injury was in fact and proximately caused by the substandard conduct. The burden of proving these elements is on the plaintiff (ie, patient) in a malpractice lawsuit. The standard of care, defined as the level of care delivered by a reasonably competent pathologist in similar circumstances, is determined based on the testimony of expert witnesses who are responsible for (1) defining a standard of care, (2) determining whether the standard of care was breached, and (3) determining whether any injury or harm was caused by the breach. To qualify as an expert witness, a pathologist must have sufficient knowledge, education, training, and/or experience relevant to the specific issue presented before the court.
Pathologists are strongly advised to notify their risk management office or malpractice insurer at the first indication of any potential medicolegal concerns with a case, although a pathologist's formal involvement in a malpractice lawsuit begins only with the service of a summons, which includes a statement of the plaintiff's complaint. Discovery takes place after a lawsuit has been filed and before the trial begins; it refers to the exchange of information concerning the lawsuit between plaintiff and defendant. One frequently used method of discovery is deposition, which consists of testimony of a witness taken under oath before a court reporter. A claim is a demand for payment. A verdict is an award by a jury. A settlement, in this context, is an agreement between the disputing parties to resolve a civil case through a negotiated solution.
Good practices prevent errors! These include but are not limited to the following: (1) Comprehensive quality assurance plan for the laboratory to limit pre-analytic, analytic, and post-analytic errors. (2) Appropriate use and integration of validated ancillary studies (special stains, flow cytometry, immunohistochemistry, molecular testing). (3) Adequate consultation in difficult, unusual cases and review of high grade and malignant diagnosis by a second pathologist. (4) Complete, clear and concise reporting with use of standardized terminology, appropriate use of addendums and amendments, and inclusion of the differential diagnosis in difficult or unusual cases. (5) Notification and documentation of critical diagnosis. (6) Continuing education of pathologists, and/or clinical colleagues. [72] [73] [74] Medical professional liability insurance, also known as malpractice insurance, protects physicians from wrongful practice resulting in bodily injury, medical expenses, and the cost of defending lawsuits related to such claims when providing professional medical services. Two types of coverage exist, occurrence policies and claims-made policies. Occurrence policies cover the insured for incidents that occurred during the policy period, regardless of when the claim was made. The date of the incident determines the coverage, even if the claim is made many years later and that particular insurance policy has expired. Claims-made policies cover the insured for incidents that occurred and were reported during the policy term, and do not cover claims made prior to the first date of coverage or claims made after the date of policy expiration. The date of reporting the incident triggers coverage for this type of policy. Upon cancellation of a claims-made policy, an extended reporting endorsement (also known as tail endorsement or tail coverage) is usually purchased so there is no lapse in coverage. This tail endorsement provides coverage for incidents that occur during a claims-made policy period but are reported after the policy has expired. If the covered physician is changing practices and the new employer agrees to pay for medical liability insurance, the new employment agreement should address who is responsible for the purchase of the tail endorsementdthe physician, the prior employer, or the new employer.
The limits of coverage available vary depending on the insurance company, state of medical practice, practitioner specialty, and practice demographics. Limits of liability are the dollar amounts of coverage for each claim and the aggregate limit for the policy term, which is usually 1 year. A policy that provides $1,000,000/$3,000,000 means that for the term of the policy, the amount of coverage for each claim is $1,000,000, and coverage for the combined number of claims is $3,000,000. Patient compensation funds are available in some states and provide coverage in addition to the primary policy. Policies also may be written to exclude certain procedures or medical practice at certain geographic locations. Medical professional liability insurance may be purchased for an individual physician, physician group, or corporate/partnership. If other health-care professionals, such as pathologists' assistants or nurse practitioners, are working under the direct supervision a physician, vicarious liability coverage is often added to the policy. Locum tenens coverage is often written as an endorsement to the employing physician's policy. 75 
Conclusion
Our trainees should be exposed to laboratory management throughout the course of their residency and fellowship training. Some pathology professional organizations provide training courses and modules related to laboratory accreditation and management. We hope that this summary document will provide guidance on topics that should be addressed during cytopathology training, such that upon graduation, cytopathologists are prepared to handle the spectrum of clinical, administrative, and accreditation requirements in their practice.
